Philips Venture Capital Fund

Philips Venture Capital Fund (Philips Ventures) is the corporate venture capital arm of Royal Philips, the Dutch multinational health technology company. Founded in 1998 and based in Amsterdam at the Amstelplein 2 Breitner Tower, Philips Ventures deploys strategic capital into early- to growth-stage health technology startups whose innovations complement Philips' global healthcare portfolio and digital transformation agenda. The fund is led by Managing Partner Nate Harrington and operates with a lean two-person team at the fund level. As a corporate and strategic investor, Philips Ventures leverages Philips' deep domain expertise, global commercial footprint, and research and development capabilities to add value to portfolio companies beyond capital alone. Investment activity focuses on Series A and Series B rounds in digital software and technology-enabled healthcare services, predominantly in US-based startups with global activity. The fund has made 22 investments across healthtech, AI, and medical devices and hardware. Notable portfolio companies include PreciseDx (diagnostic equipment, latest investment as part of a Series B-II round in June 2025 as the firm's most recent disclosed deployment), Endovascular Engineering, and R3 Vascular. Recorded exits include Carevive Systems in June 2024 and ALung, acquired by LivaNova in May 2022. The firm currently states it is not investing in development-stage or pre-clinical businesses. Philips Ventures focuses on innovations that can reduce costs, improve clinical outcomes, and transform the patient and clinician experience in ways that align with Philips' strategic roadmap. Portfolio companies benefit from the potential to pilot solutions within Philips' customer network, access the firm's technical talent, and leverage its global healthcare commercial relationships across hospitals, imaging centers, and health systems worldwide.